Streetbeat News

Earnings

IBTX

Independent Bank Gr (NASDAQ:IBTX) reported Q4 adjusted EPS of $0.62, missing the consensus estimate of $0.67 by 7.46%, and a 48.33% decrease from $1.20 per share a year ago. Sales were $118.67M, missing estimates by 4.16% and down 22.69% from $153.50M in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 10:11 pm

SMBK

SmartFinancial (NASDAQ:SMBK) reported Q4 adjusted EPS of $0.41, meeting analyst estimates, but representing a 46.05% decrease from the previous year. Sales were $39.10M, slightly beating estimates by 0.07% but showing a 12.61% decrease from the prior year's sales.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 10:09 pm

YS

YS Biopharma reported a half-year loss per share of $(0.26) and a net loss of $(24.3) million. The company's cash and cash equivalents decreased to RMB259.9 million ($36.2 million) as of September 30, 2023, from RMB370.4 million as of March 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 10:08 pm

AGYS

Agilysys, Inc. (NASDAQ:AGYS) reported Q3 earnings of $0.35 per share, surpassing estimates of $0.26. Sales reached $60.60 million, exceeding expectations and marking a 21.39% increase year-over-year. Gross margin improved to 62.5%, and free cash flow was $11.3 million. The company maintained its full-year 2024 revenue guidance and raised its adjusted EBITDA outlook. Despite positive results, AGYS shares dropped 3.10% in after-hours trading.

Portfolio Pulse from Ryan Gustafson

January 22, 2024 | 10:05 pm

BMY

EXEL

Bristol Myers Squibb (BMY) and Exelixis, Inc. (EXEL) announced positive four-year follow-up results from the CheckMate -9ER trial for Opdivo and CABOMETYX in treating advanced renal cell carcinoma. The combination showed superior progression-free survival, objective response rates, and overall survival compared to sunitinib. The results, which also include health-related quality-of-life benefits, will be presented at the ASCO 2024 Genitourinary Cancers Symposium.

Portfolio Pulse from Charles Gross

January 22, 2024 | 10:02 pm

HBCP

Home Bancorp reported a decrease in earnings per share (EPS) for Q4, with a current EPS of $1.17 compared to $1.32 in the prior year.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 10:02 pm

ECO

Okeanis Eco Tankers Corp. (NYSE:ECO) provided a commercial update for Q4 2023, estimating a fleetwide Daily Time Charter Equivalent Rate (Daily TCE Rate) of approximately $45,300 per operating day. The estimated Daily TCE Rates for VLCC and Suezmax vessels were $45,200 and $45,500 per operating day, respectively, with Suezmax spot days at $51,800. For Q1 2024, 61% of VLCC and 41% of Suezmax spot days have been booked at $76,100 and $59,300, respectively. The Daily TCE Rate is a non-GAAP and non-IFRS measure, and the company has not finalized its financial statements for 2023, indicating that the provided figures are preliminary and subject to change.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 9:40 pm

RBB

RBB Bancorp (NASDAQ:RBB) exceeded analyst expectations for Q4 with an adjusted EPS of $0.45, surpassing the estimate of $0.35 by 28.57%. However, this represents a 51.09% decrease from the previous year's EPS of $0.92. Sales reached $33.06M, beating the $27.81M estimate by 18.89% but showing a 20.03% decline from the prior year's $41.34M.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 9:39 pm

BVFL

BV Financial, Inc. reported earnings per share (EPS) of $0.28 for the quarter ended December 31, 2023, a decrease from $0.34 year-over-year.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 9:39 pm

OEC

Orion Engineered Carbons S.A. (OEC) anticipates its 2023 results to be at the lower end of its previously provided adjusted EBITDA guidance range of $330 million to $350 million.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 9:37 pm